يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Harousseau, JL"', وقت الاستعلام: 1.02s تنقيح النتائج
  1. 1
    Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

    المؤلفون: Kumar, S, Giralt, S, Stadtmauer, Ea, Harousseau, Jl, Palumbo, Antonio, Bensinger, W, Comenzo, Rl, Lentzsch, S, Munshi, N, Niesvizky, R, San Miguel, J, Ludwig, H, Bergsagel, L, Blade, J, Lonial, S, Anderson, Kc, Tosi, P, Sonneveld, P, Sezer, O, Vesole, D, Cavo, M, Einsele, H, Richardson, Pg, Durie, Bg, Rajkumar, Sv, International Myeloma Working Group

    المساهمون: Radiology & Nuclear Medicine, Hematology, Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV, International Myeloma Working Group.

    المصدر: Blood, 114(9), 1729-1735. American Society of Hematology

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Consensus Development Conferences as Topic, medicine.medical_treatment, Immunology, Antineoplastic Agents, Hematopoietic stem cell transplantation, Medical Oncology, Biochemistry, Bortezomib, Autologous stem-cell transplantation, Internal medicine, medicine, Humans, Lenalidomide, Multiple myeloma, Hematopoietic Stem Cell Mobilization, Clinical Trials as Topic, business.industry, Hematopoietic Stem Cell Transplantation, Cell Biology, Hematology, medicine.disease, Boronic Acids, Combined Modality Therapy, Thalidomide, Pyrazines, Stem cell, Multiple Myeloma, business, Immunosuppressive Agents, medicine.drug

    وصف الملف: STAMPA

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31d4e2b9acf06cf934693ee79b02e3f0Test
    https://pure.eur.nl/en/publications/c37dbdad-e9fe-4602-9985-9ff0a3ac0918Test


    أضف إلى المفضلة
  2. 2
    Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

    المؤلفون: Paul G. Richardson, Helgi van de Velde, Jean-Luc Harousseau, Dixie-Lee Esseltine, Rudolf Schlag, Maria-Victoria Mateos, Antonio Palumbo, Ofer Shpilberg, Andrew Cakana, Kevin Liu, Jesús F. San Miguel, Alain Kentos, Anatoly Golenkov, Meletios A. Dimopoulos, Martin Kropff, Mieczysław Komarnicki, Michele Cavo, William Deraedt

    المساهمون: Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, Komarnicki M, Mateos MV, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF.

    المصدر: Digital.CSIC. Repositorio Institucional del CSIC
    instname

    مصطلحات موضوعية: Melphalan, Male, medicine.medical_specialty, Time Factors, medicine.drug_class, Immunology, Urology, Kaplan-Meier Estimate, Biochemistry, Bortezomib, chemistry.chemical_compound, Prednisone, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Multiple myeloma, Aged, Very Good Partial Response, business.industry, Hazard ratio, Remission Induction, Cell Biology, Hematology, Middle Aged, medicine.disease, Prognosis, Boronic Acids, Nitrogen mustard, Surgery, Treatment Outcome, chemistry, Pyrazines, Multivariate Analysis, Corticosteroid, Female, business, Multiple Myeloma, medicine.drug

    وصف الملف: STAMPA

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b7575c14625ec3fee0597f02beab88Test
    http://hdl.handle.net/10261/63102Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث